Welcome to our dedicated page for Cardio Diagnostics Holdings SEC filings (Ticker: CDIOW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Cardio Diagnostics Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Cardio Diagnostics Holdings's regulatory disclosures and financial reporting.
On September 18, 2026, Cardio Diagnostics Holdings, Inc. (CDIO) held its annual meeting of stockholders, with 1,783,220 of 2,959,469 eligible common shares present or represented by proxy, a turnout of approximately 60.25%. Stockholders elected seven directors to one-year terms under a plurality vote standard.
They also approved a proposal permitting future issuance of shares of common stock and/or convertible or exercisable securities equal to 20% or more of the common stock outstanding in one or more non-public transactions, as required by Nasdaq Marketplace Listing Rule 5635(d). In addition, stockholders ratified the appointment of Prager Metis CPA’s LLC as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Cardio Diagnostics Holdings, Inc. (CDIO) reported that senior management is using a new August 2026 investor presentation to brief existing and prospective investors. The company focuses on AI- and epigenetics-based blood tests for cardiovascular disease risk stratification (Epi+Gen CHD) and diagnosis (PrecisionCHD), supported by a proprietary multi-omics engine and a growing IP portfolio across multiple jurisdictions.
The presentation highlights large estimated U.S. market opportunities for these tests, a company-owned CLIA lab intended to lower costs and increase capacity, and progress toward reimbursement, including specific CPT PLA codes, a final CMS payment rate, and initial commercial coverage. It also outlines ongoing and planned clinical, economic, and utility studies, as well as U.S. and international commercialization efforts. The investor materials are furnished under Regulation FD and are not deemed filed or incorporated by reference into Securities Act filings.
Cardio Diagnostics Holdings develops AI‑driven blood tests for cardiovascular disease. For the quarter ended June 30, 2026, it generated revenue of $5,360 and incurred a net loss of $1,501,468, or $0.51 per share, on operating expenses of $1,503,507.
For the first six months of 2026, revenue was $8,040 with a net loss of $3,289,626. Cash was $5,586,697 at June 30, 2026, and stockholders’ equity totaled $7,426,283, against total liabilities of $499,780.
The company continues to fund operations primarily through equity, including $3,693,470 of net proceeds from at‑the‑market share sales in 2026. With 2,959,469 shares outstanding, management notes ongoing operating losses, modest revenue to date, and dependence on future capital raises and broader test adoption.
Cardio Diagnostics Holdings, Inc. plans a virtual annual stockholder meeting on September 18, 2026, where holders of 2,959,469 common shares as of July 31, 2026 can vote. Stockholders will elect seven directors, approve a new share-issuance authorization, and ratify Prager Metis CPA’s LLC as auditor for 2026.
The core item is the 2026 Issuance Proposal, which would permit, in one or more non-public transactions, the future sale of up to 5.0 million shares of common stock (or equivalents) for up to $10.0 million, at discounts up to 25% below market, within three months of approval (extendable to six months with Nasdaq consent), in compliance with Nasdaq Listing Rule 5635(d). If fully used, outstanding shares could rise to about 7,959,469, an increase of approximately 169%.
The company explains this authority is intended to provide an alternative capital-raising tool alongside its existing at-the-market facility, under which it has already raised about $18.75 million and issued 2,251,181 shares. The proxy discusses potential effects of any such financing, including dilution of existing ownership, possible share-price pressure, and anti-takeover implications, and outlines the board’s governance structure, committee composition, and emerging growth company status.
Cardio Diagnostics Holdings, Inc. director Peter K. Fung received a grant of stock options as part of his compensation. On June 30, 2026, he was awarded 2,854 stock options with a conversion price of $2.19 per share, each option representing the right to buy one share of common stock. These are classified as a grant or award, not an open-market purchase or sale. Following this award, Fung holds a total of 12,367 stock options linked to Cardio Diagnostics common stock, giving him additional potential future ownership if he chooses to exercise the options before they expire in 2036.
Cardio Diagnostics Holdings, Inc. director Wendy J. Betts received a grant of stock options covering 2,854 shares of common stock. The options have an exercise price of $2.19 per share and expire on June 30, 2036. This is a compensation-related award, not an open-market trade, and brings her directly held option awards to a total of 12,367 underlying shares.
Cardio Diagnostics Holdings director James Intrater received a new stock option grant as part of his compensation. On June 30, 2026, he was granted options to acquire 2,854 shares of common stock at an exercise price of $2.19 per share, expiring on June 30, 2036. After this award, he directly holds options for 13,318 shares in total.
Cardio Diagnostics Holdings director Burton Paul Frederick received a grant of stock options, providing additional equity-based compensation. The award covers 2,854 options to buy Common Stock at an exercise price of $2.19 per share, expiring on June 30, 2036. Following this grant, Frederick holds 13,318 stock options directly.
Cardio Diagnostics Holdings, Inc. reported a first-quarter 2026 net loss of $1,788,158 on very early-stage revenue of $2,680, reflecting continued investment ahead of broad commercialization. Operating expenses were $1,787,517, driven mainly by general and administrative costs, sales and marketing, and research and development.
Cash increased to $7,077,021 as of March 31, 2026, helped by $3,693,470 in net proceeds from at-the-market common stock sales, leaving stockholders’ equity at $8,903,399. The company continues to expand adoption of its AI-driven cardiovascular tests, build evidence, and rely on equity financing while acknowledging its disclosure controls were not effective.
Cardio Diagnostics Holdings, Inc. director Peter K. Fung received a grant of stock options for 3,205 shares of Common Stock at an exercise price of $1.95 per share on March 31, 2026. Following the grant, he holds stock options for a total of 9,513 shares, expiring on March 31, 2036.